
The U.S. Food and Drug Administration (FDA) announced on its official website on June 14th that the Federal District Court of Colorado has issued a permanent injunction against Boosted LLC (dba Boosted E-Juice, Boosted, Live Boosted) and its owner Cory Vigil. The ruling prohibits them from manufacturing, selling, or distributing any new tobacco products unless they meet certain requirements.
According to a lawsuit filed by the US Department of Justice (DOJ) on behalf of the FDA, the defendant has been warned for serious violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) regarding pre-market review requirements for new tobacco products, as they did not obtain market authorization from the FDA before selling them. The FDA has warned that continued violations may lead to further legal action, including injunctions.
In order to avoid litigation, the defendant signed a consent judgment, which is a written agreement signed by a federal judge and issued as a court order. According to the consent judgment, the defendant agreed not to manufacture, sell, or distribute any new tobacco products until certain requirements are met. These requirements include obtaining FDA marketing authorization for the new tobacco products, FDA inspecting the defendant's facilities to determine compliance with the law, and FDA notifying the defendant in writing that they appear to be in compliance with the law.
The FDA and the Department of Justice have initiated an injunction for the eighth time, beginning in October 2022, in order to enforce pre-market review requirements for new tobacco products. The Department of Justice has taken legal action in court under the Federal Food, Drug, and Cosmetic Act. Therefore, on behalf of the FDA, the Department of Justice filed consent decrees for permanent injunction against defendants in the district of Colorado (each manufacturer's respective U.S. District Court).
FDA Center for Tobacco Products (CTP) Director Brian King stated:
The FDA consistently and resolutely enforces the law, especially after issuing clear warnings and explaining what companies need to do to comply. Those who disregard the law will be held accountable, and we are committed to using all our powers to hold them responsible.
The FDA has made it clear that it will work together with federal partners, including the Department of Justice, to take enforcement actions and seek permanent injunctions against illegal behavior.
This action is part of a comprehensive approach to coordinated enforcement by the FDA and other federal agencies. Last year, in a joint operation at Los Angeles International Airport, the U.S. Customs and Border Protection seized over $18 million worth of illegal e-cigarettes. In addition, the FDA has issued 678 warning letters to companies suspected of manufacturing, selling, and/or distributing unauthorized novel tobacco products, issued over 550 warning letters to retailers, filed civil penalty complaints against 57 manufacturers and 140 retailers for selling unauthorized tobacco products.
The eight manufacturers who received permanent injunctions are as follows:

We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com